Non-coding RNAs as regulators of the Hippo pathway in cardiac development and cardiovascular disease

Front Pharmacol. 2024 Apr 18:15:1348280. doi: 10.3389/fphar.2024.1348280. eCollection 2024.

Abstract

Cardiovascular diseases pose a serious threat to human health. The onset of cardiovascular diseases involves the comprehensive effects of multiple genes and environmental factors, and multiple signaling pathways are involved in regulating the occurrence and development of cardiovascular diseases. The Hippo pathway is a highly conserved signaling pathway involved in the regulation of cell proliferation, apoptosis, and differentiation. Recently, it has been widely studied in the fields of cardiovascular disease, cancer, and cell regeneration. Non-coding RNA (ncRNAs), which are important small molecules for the regulation of gene expression in cells, can directly target genes and have diverse regulatory functions. Recent studies have found that ncRNAs interact with Hippo pathway components to regulate myocardial fibrosis, cardiomyocyte proliferation, apoptosis, and hypertrophy and play an important role in cardiovascular disease. In this review, we describe the mode of action of ncRNAs in regulating the Hippo pathway, provide new ideas for further research, and identify molecules involved in the mechanism of action of ncRNAs and the Hippo pathway as potential therapeutic targets, with the aim of finding new modes of action for the treatment and prevention of cardiovascular diseases.

Keywords: Hippo pathway; cardiovascular development; cardiovascular disease; circRNA; lncRNA; microRNA.

Publication types

  • Review

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was supported by grants from the Science and Technology Development Program of Jilin province (No. 20220303002SF), the Development and Reform Commission of Jilin province (No. 2022C003), the Health Science and Technology Capacity Improvement Project of Jilin province (No. 2021LC016) and the National Clinical Key Specialty Project.